|
1
|
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
|
J Urol
|
2003
|
3.82
|
|
2
|
Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent.
|
Cancer
|
2008
|
3.06
|
|
3
|
The learning curve for surgical margins after open radical prostatectomy: implications for margin status as an oncological end point.
|
J Urol
|
2010
|
2.61
|
|
4
|
Pathological features of lymph node metastasis for predicting biochemical recurrence after radical prostatectomy for prostate cancer.
|
J Urol
|
2012
|
2.15
|
|
5
|
Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness.
|
Radiology
|
2011
|
2.10
|
|
6
|
Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.
|
J Clin Oncol
|
2012
|
1.82
|
|
7
|
Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer.
|
J Urol
|
2012
|
1.64
|
|
8
|
Advances in magnetic resonance imaging: how they are changing the management of prostate cancer.
|
Eur Urol
|
2011
|
1.63
|
|
9
|
How do you know if you are any good? A surgeon performance feedback system for the outcomes of radical prostatectomy.
|
Eur Urol
|
2011
|
1.50
|
|
10
|
Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence.
|
Int J Radiat Oncol Biol Phys
|
2007
|
1.31
|
|
11
|
Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer.
|
BJU Int
|
2011
|
1.26
|
|
12
|
Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading.
|
BJU Int
|
2007
|
1.21
|
|
13
|
Haralick texture analysis of prostate MRI: utility for differentiating non-cancerous prostate from prostate cancer and differentiating prostate cancers with different Gleason scores.
|
Eur Radiol
|
2015
|
1.16
|
|
14
|
p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer.
|
BJU Int
|
2009
|
1.06
|
|
15
|
Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer.
|
Brachytherapy
|
2006
|
1.04
|
|
16
|
Electronic patient self-assessment and management (SAM): a novel framework for cancer survivorship.
|
BMC Med Inform Decis Mak
|
2010
|
0.98
|
|
17
|
Algorithms for prostate-specific antigen recurrence after treatment of localized prostate cancer.
|
Clin Prostate Cancer
|
2003
|
0.98
|
|
18
|
Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature.
|
Eur Urol
|
2012
|
0.98
|
|
19
|
Impact of socioeconomic factors on prostate cancer outcomes in black patients treated with surgery.
|
Urology
|
2008
|
0.94
|
|
20
|
Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: implications for screening.
|
Urology
|
2003
|
0.94
|
|
21
|
Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer.
|
Urology
|
2010
|
0.94
|
|
22
|
Testosterone in prostate cancer: the Bethesda consensus.
|
BJU Int
|
2011
|
0.90
|
|
23
|
Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.
|
Eur Urol
|
2012
|
0.89
|
|
24
|
Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
|
Urol Oncol
|
2006
|
0.88
|
|
25
|
Subjective characterization of nerve sparing predicts recovery of erectile function after radical prostatectomy: defining the utility of a nerve sparing grading system.
|
J Sex Med
|
2010
|
0.88
|
|
26
|
The association between tumour density and prostate cancer recurrence following radical prostatectomy.
|
Can Urol Assoc J
|
2011
|
0.88
|
|
27
|
Prostate biopsy techniques and indications: when, where, and how?
|
Semin Urol Oncol
|
2002
|
0.86
|
|
28
|
What has to happen before we report radical prostatectomy outcomes of individual surgeons to the public?
|
Urol Oncol
|
2010
|
0.83
|
|
29
|
Prevalence of HOXB13 mutation in a population of Ashkenazi Jewish men treated for prostate cancer.
|
Fam Cancer
|
2013
|
0.79
|
|
30
|
Outcomes following negative prostate biopsy for patients with persistent disease after radiotherapy for prostate cancer.
|
Int Braz J Urol
|
2010
|
0.78
|
|
31
|
Defining the impact of vascular risk factors on erectile function recovery after radical prostatectomy.
|
BJU Int
|
2012
|
0.76
|
|
32
|
Postoperative systems models more accurately predict risk of significant disease progression than standard risk groups and a 10-year postoperative nomogram: potential impact on the receipt of adjuvant therapy after surgery.
|
BJU Int
|
2011
|
0.75
|
|
33
|
Maintaining bone health in prostate cancer throughout the disease continuum.
|
Semin Oncol
|
2010
|
0.75
|
|
34
|
Trends and Clinical Practice Patterns of Sacral Neuromodulation for Overactive Bladder.
|
Female Pelvic Med Reconstr Surg
|
2017
|
0.75
|